In this recent paper finds CALR-mutated ET, CALR variant allele frequency & high molecular risk mutations predict cytoreductive response & key outcomes better than CALR mutation type. Highlighting VAF as a marker of lower response & higher thrombosis & MF risk.
👉https://bit.ly/4rRMRcf
This 🔥HemaTopics by Sci Ed L Merz highlights a growing gap btwn research criteria & bedside care in obs antiphospholipid syndrome, arguing that pts who meet the 2006 criteria may still warrant aspirin ➕ anticoagulation, even if they no longer meet the 2023 criteria 👉https://bit.ly/4lHLGKW
After showing ruxolitinib’s promise in immune aplastic anemia, authors explore selective JAK inhibition to refine therapy & reduce toxicity. #HemaSphere. #Hematology. #Jakinhibitors
Read more about it here👉https://bit.ly/4blYqmX
Don't have plans? A powerful new theatre piece, created with our Scientific Ed S. Hibbs, brings to life the realities of sickle cell crises and reimagines what good care could be. Showing at BSH ASM + across London. Info: www.crescentcell.com #BSH2026
This paper in the March issue shows PBMC multi-omics can distinguish #SCD, PH & #SCD–PH using clear immune-metabolic signatures, including iron loading, arginine disruption & oxidative stress; highlighting PBMCs as an accessible route to stratification & biomarkers 👉https://bit.ly/4bxxO2s
This paper shows how NCOA2 helps hematopoietic stem cells recover after irradiation by reducing mitochondrial stress and restoring quiescence. The authors reveal a FOXO3a‑dependent mitophagy pathway that preserves long‑term stem cell function. Read more 👉https://bit.ly/4b9djrr
Great job, authors! Congrats on this important publication.
This paper questions severity‑based treatment for #iMCD‑IPL. The authors show that patients labelled “severe” have outcomes similar to non‑severe disease, with no clear benefit from treatment intensification, supporting subtype‑informed management. Learn more here 👉https://bit.ly/4ruiSYH
Clonal hematopoiesis in #CLL affects survival, treatment toxicity, and transformation risk. The authors link specific mutations to poorer outcomes and immune changes, highlighting why CH matters in clinical decision‑making.
Read more https://bit.ly/4rv9hRd
Authors in this paper show that bone marrow plasma cell counts add little once serum immunofixation is negative, demonstrating that mass spectrometry better detects residual disease & prognosis, offering a more accurate, noninvasive way to assess response 👉https://bit.ly/4rYzoQb
In this recent paper, authors present a simple flow cytometry prognostic score for myelodysplastic neoplasms. It predicts overall survival and improves risk stratification beyond current scores, supporting earlier, more precise clinical decisions.
Learn more.👉https://bit.ly/3ZPiwiM
🚨 In this extended episode host Sci Ed Charles de Bock discusses #SCD w/ co-authors, covering both expert & lived-patient perspectives
This episode is on our website & all major podcast platforms. Listen & enjoy casual, insightful discussions about #hematology research https://bit.ly/4nIhH68
This paper highlights how targeted therapies and #CAR‑T are achieving increasingly deep remissions in #CLL, raising possibilities of true/functional cure for selected patients. The authors provide insights that may reshape long‑term expectations for disease control 👉https://bit.ly/4kVc0Rj
Authors show that bone marrow fibrosis is driven by reprogrammed stromal and osteolineage cells through Wnt signaling, demonstrating that blocking this pathway reduces fibrosis, highlighting a potential therapeutic target.
Read more to explore the implications👉
Current phase III trial eligibility criteria exclude nearly half of real‑world patients with #ALamyloidosis. Authors highlight how this gap affects outcomes and why broader, more inclusive trial designs are needed.
Read more to explore the implications👉https://bit.ly/3ObpM6n
Flow cytometry #MRD risk is not uniform in #AML. In this paper, authors show that the type and burden of immunophenotypic abnormalities refine relapse risk, identifying MRD‑positive patients with outcomes similar to MRD‑negative disease.
Read more 👉https://bit.ly/3ZsbOPX
A registration check in desk for attendees, with 3 black and pink banners showing the EHA name and the word "registration", and beige tote bags for distribution.
To those attending #EHARecon2026, we look forward to welcoming you here in Espoo. It's going to be a great 4 days of science, networking, and fun. Plus, lovely fresh Finnish air 🙌.
This clinical best practice guideline highlights the need to assess #CLL patient fitness beyond age. The authors show that evaluating comorbidities, functional status, and overall resilience supports safer, more personalized treatment decisions.
Read more here 👉https://bit.ly/4c0hXu3
The March issue is now open!
Find the hottest hematology research here👉 https://bit.ly/4siu5f2
Better yet, sign up for email alerts 👉https://bit.ly/4bERf8C
Deep learning analysis of over 1500 #CML marrow slides reveals overlooked cytomorphologic features that strongly predict TKI response. A new Morphoclinical model markedly outperforms current risk scores, supporting more precise frontline therapy selection in CML. 👉https://bit.ly/4rP6imf
This paper shows that Tet2 is essential for controlling how IgG1⁺ germinal center B cells mature. The authors reveal that Tet2 loss disrupts the balance between proliferation and differentiation, offering insight into mechanisms that may drive DLBCL transformation 👉https://bit.ly/4pI3Psx
The authors report that IMWG‑FI–defined frail patients form a diverse group, with ultra‑frail patients facing very limited survival. Their findings stress the value of including frailty categories in future research and clinical planning.
Read more here 👉https://bit.ly/4pw4iim
Real-world cases illustrate how luspatercept use in transfusion-dependent β-thalassemia hinges on genotype-informed selection, patient engagement, and nuanced monitoring of efficacy and safety, offering practical insights beyond clinical
trial data.
Read the details here👉https://bit.ly/46KtU3u
This issue highlights research on clonal hematopoiesis in #CLL/Richter transformation, TKI response patterns in #CML, venetoclax‑based therapy outcomes in #AML, challenges in #AL amyloidosis trial eligibility & advances in #MRD & flow‑cytometry–based prognostics. 👉https://bit.ly/4qFeK6Q
Venetoclax-sensitizing genomics drive markedly better outcomes in therapy-related AML, where venetoclax-based regimens boost responses and enable more patients to reach transplant, while TP53 and RAS mutations continue to limit survival.
https://bit.ly/4rJdb8M
This paper shows that memantine was safe and well tolerated in patients with sickle cell disease #SCD. Authors report reduced red blood cell K⁺ loss and improved hemoglobin at low doses, suggesting a promising supportive therapy.
Delve deeper 📰 https://bit.ly/3YAax8P
This paper shows that IGHV gene usage and a 97% IGHV identity cutoff offer meaningful prognostic insight in #mantlecell lymphoma. The authors provide evidence that immunoglobulin repertoire patterns may help refine risk assessment. Explore the full analysis 👉 https://bit.ly/4qD0SLi
Authors explore how to distinguish defective vs. ineffective erythropoiesis, offering insights into mechanisms underlying anemia & hematologic disorders. https://bit.ly/4jTjsfl
@ElHoss_Sara
This paper shows that adult #LBCL with IRF4 rearrangement is biologically diverse. The authors highlight how age, tumor site, and molecular features together can refine diagnosis and support more precise risk assessment and management.
Go in depth here 👉https://bit.ly/49KYlqU
Fabulous! Congratulations and well done.
